“Dual Neutralization of IL-17A and IL-17F With Bimekizumab Improves Quality of Life in Patients Withmoderate-to-Severe Plaque Psoriasis: Results from a Phase 2b Study and Correlation With Clinical Response”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S92. Accessed April 29, 2026. https://skin.dermsquared.com/skin/article/view/489.